ArticleFrontiers in pediatrics2025
Study on the influencing factors of the first-line treatment response to primary immune thrombocytopenia in children.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of a predictive model for chronic or persistent immune thrombocytopenia in children incorporating anti-glycoprotein IIb antibody: a retrospective cohort study utilizing LASSO regression and bootstrap stability analysis.Frontiers in pediatrics · 2026Article
- Freely accessible large language models for parent education in pediatric immune thrombocytopenia: an expert-rated cross-sectional study of safety, readability, and guideline concordance.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study aims to investigate the factors influencing the first-line treatment response in children with primary immune thrombocytopenia (ITP) and to evaluate the predictive value of these indicators for therapeutic outcomes. Methods: A total of 140 pediatric patients diagnosed with ITP at the Pediatrics Department of the First Affiliated Hospital of Shihezi University, between June 2022 and December 2024, were enrolled. Patients were grouped according to the type of first-line treatment and treatment response. Laboratory tests such as platelet parameters, P-glycoprotein (P-gp), T lymphocyte subsets, immunoglobulins, and complements were collected and analyzed. Results: Multivariate logistic regression analysis identified elevated P-gp and platelet-to-lymphocyte ratio (PLR), decreased of CD4 Conclusions: Elevated P-gp and PLR, along with reduced CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.